• IRadimed’s third-quarter 2026 diluted EPS rose 17% year-over-year to $0.51; revenue climbed 14% to $24.2 million.
• The new 3870 MR IV pump launch drove record quarterly revenue, while bookings also reached a record.
• Full-year 2026 revenue guidance narrowed to $91.6 million-$93.1 million; diluted EPS guidance narrowed to $1.90-$1.94.
• Fourth-quarter 2026 guidance calls for revenue of $25 million-$26.5 million and diluted EPS of $0.53-$0.57.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IRadimed Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610300830PRIMZONEFULLFEED9856709) on October 30, 2026, and is solely responsible for the information contained therein.